No intervention
OtherAs this is an observational study, no intervention will be administered.
NCT Number: NCT05982717
The main aims of this study are to gather information about how many children, teenagers and adults in Spain have been diagnosed with Dravet syndrome and Lennox-Gastaut syndrome as well as to learn about the number of new Dravet syndrome and Lennox-Gastaut syndrome cases in persons in Spain.
Participants' data will be taken from their medical records (charts), which were already collected as a part of their routine care in public hospitals in Spain between 01 January 2021 and 31 December 2022.
Looking for future studies?
Notify MeAll sexes
Observational
Complejo Hospitalario Universitario de Vigo, Vigo, Pontevedra, Spain
This is a non-interventional, retrospective study of participants from Spain with DS and LGS at public hospitals. The participants will be identified from their medical charts or hospital records and those who meet the eligibility criteria will be included.
This multi-center trial will be conducted in Spain. Data will be retrospectively collected for the observation period between 01 January 2021 to 31 December 2022. The total duration of the study is approximately 24 months.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
A. Diagnosis criteria for DS:
iii. Recurrent focal clonic (hemiclonic) febrile and afebrile seizures (which often alternate sides from seizure to seizure), focal to bilateral tonicclonic, and/or generalized clonic seizures.
ii. Seizures triggered by fever due to illness or vaccinations, hot baths, sudden temperature changes, high level of activity, or by strong lighting or exposure to certain visual patterns.
iii. Mutations or copy number variants in the SCN1A gene.
B. Diagnosis criteria for LGS:
Given the uncertainties associated with the diagnosis of this condition, two different criteria will be used, a stricter criterion, intended to identify "pure" Lennox-Gastaut syndrome participants, and a wider criterion, intended to also include the so-called Lennox-Gastaut-like participants.
Lennox-Gastaut syndrome - stricter criteria:
Lennox-Gastaut syndrome - wider criteria:
i. Tonic seizures. ii. Multiple types of seizures, including generalised tonic-clonic seizures, atypical absence seizures, atonic seizures, myoclonic seizures, myoclonic-atonic seizures, focal seizures, epileptic spams, or nonconvulsive status epilepticus.
i. Slow (<2.5 Hz) spike-and-wave EEG pattern. ii. Paroxysmal fast activity (10 Hz or greater) in sleep.
i. Seizures onset before 18 years of age, typically from 1 to 8 years. ii. Progressive development/cognition impairment after seizures onset. iii. Development/cognition impairment starts prior to seizures onset. iv. History of Infantile epileptic spasms syndrome (IESS), West or Ohtahara syndromes.
Exclusion criteria
As this is an observational study, no intervention will be administered.
Time frame: Up to 12 months
Number of participants with DS over a period of one year will be assessed.
Time frame: At two different 12 month periods (in consecutive years at Months 12 and 24)
Number of new participants diagnosed annually with DS yearly.
Time frame: Up to 12 months
Number of participants with LGS over a period of one year based on stricter diagnosis criterion will be assessed.
Time frame: At two different 12 month periods (in consecutive years at Months 12 and 24)
Number of new participants diagnosed annually with LGS based on stricter diagnosis criterion.
Time frame: Up to 12 months
Number of participants with LGS over a period of one year based on wider diagnosis criterion will be assessed.
Time frame: At two different 12 month periods (in consecutive years at Months 12 and 24)
Number of new participants diagnosed annually with LGS based on wider diagnosis criterion.
Time frame: Up to 12 months
Number of participants with paediatric DS over a period of one year will be assessed.
Time frame: Up to 12 months
Number of participants with paediatric LGS over a period of one year based on stricter and wider diagnoses criteria will be assessed.
Time frame: Up to 12 months
Number of participants with adult DS over a period of one year will be assessed.
Time frame: Up to 12 months
Number of participants with adult LGS over period of one year based on stricter and wider diagnoses criteria will be assessed.
Time frame: At two different 12 month periods (in consecutive years at Months 12 and 24)
Number of new paediatric participants diagnosed annually with DS.
Time frame: At two different 12 month periods (in consecutive years at Months 12 and 24)
Number of new paediatric participants diagnosed annually with LGS based on stricter and wider diagnoses criteria.
Time frame: At two different 12 month periods (in consecutive years at Months 12 and 24)
Number of new adult participants diagnosed annually with DS.
Time frame: At two different 12 month periods (in consecutive years at Months 12 and 24)
Number of new adult participants diagnosed annually with LGS based on stricter and wider diagnoses criteria.
Time frame: Up to 12 months
Time frame: Up to 12 months
Time frame: Up to 12 months
Time frame: Up to 12 months
Time frame: At two different 12 month periods (in consecutive years at Months 12 and 24)
Annually diagnosed DS participants will be categorized based on gender distribution at diagnosis.
Time frame: At two different 12 month periods (in consecutive years at Months 12 and 24)
Annually diagnosed LGS participants will be categorized based on gender distribution at diagnosis.
Time frame: At two different 12 month periods (in consecutive years at Months 12 and 24)
Annually diagnosed DS participants will be categorized based on age distribution at diagnosis.
Time frame: At two different 12 month periods (in consecutive years at Months 12 and 24)
Annually diagnosed LGS participants will be categorized based on age distribution at diagnosis.
Time frame: At two different 12 month periods (in consecutive years at Months 12 and 24)
Annually diagnosed DS participants will be categorized based on gender distribution at symptoms onset.
Time frame: At two different 12 month periods (in consecutive years at Months 12 and 24)
Annually diagnosed LGS participants will be categorized based on gender distribution at symptoms onset.
Time frame: At two different 12 month periods (in consecutive years at Months 12 and 24)
Annually diagnosed DS participants will be categorized based on age distribution at symptoms onset.
Time frame: At two different 12 month periods (in consecutive years at Months 12 and 24)
Annually diagnosed LGS participants will be categorized based on age distribution at symptoms onset.
Time frame: At two different 12 month periods (in consecutive years at Months 12 and 24)
Diagnosis delay is defined as time from symptoms onset to diagnosis.
Time frame: At two different 12 month periods (in consecutive years at Months 12 and 24)
Diagnosis delay is defined as time from tonic seizures onset to electroencephalography (EEG) confirmation.
Time frame: At two different 12 month periods (in consecutive years at Months 12 and 24)
Time frame: At two different 12 month periods (in consecutive years at Months 12 and 24)
Time frame: At two different 12 month periods (in consecutive years at Months 12 and 24)
Time frame: At two different 12 month periods (in consecutive years at Months 12 and 24)
Takeda
Industry
Epidemiology of Dravet and Lennox-Gastaut Syndromes in Spain
Acronym: DRALEGA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06924827
Brain Diseases, Central Nervous System Diseases
Toronto, Ontario, Canada
View Trial DetailsNCT06738732
Brain Diseases, Central Nervous System Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT07225231
Brain Diseases, Central Nervous System Diseases
View Trial DetailsNCT04940624
Brain Diseases, Central Nervous System Diseases
Phoenix, Arizona, United States
View Trial Details